mXELIRI和mFOLFIRI方案联合西妥昔单抗一线治疗转移性左半结肠癌的临床观察CSCD

目的初步比较mXELIRI与mFOLFIRI方案联合西妥昔单抗一线治疗转移性左半结肠癌的临床疗效及安全性。方法回顾性分析68例接受西妥昔单抗联合mXELIRI或mFOLFIRI方案治疗的转移性左半结肠癌患者临床资料,比较西妥昔单抗联合两种化疗方案的客观缓解率(ORR)、疾病控制率(DCR)及无进展生存时间(PFS),并评估安全性。结果mXELIRI组和mFOLFIRI组的客观缓解率分别为62.5%和58.4%,疾病控制率为87.5%和88.9%,中位PFS分别为10.5和9.9月,差异均无统计学意义(均P>0.05);mXELIRI组手足综合征发生率明显高于mFOLFIRI组(37.5%vs.13.9%,P=0.025)。结论西妥昔单抗联合mXELIRI或mFOLFIRI方案一线治疗转移性左半结肠癌的疗效及安全性相当。

Clinical Observation of mXELIRI and mFOLFIRI Combined with Cetuximab in Firstline Treatment of Metastatic Left-side Colon Cancer

Objective To compare the clinical efficacy and safety between mXELIRI and mFOLFIRI combined with cetuximab in the first-line treatment of metastatic left-side colorectal cancer. Methods We retrospectively analyzed the clinical data of 68 patients with metastatic left-side colorectal cancer treated with cetuximab combined with mXELIRI or mFOLFIRI. We compared the objective response rate (ORR), disease control rate (DCR) and progression-free survival time (PFS) between two regimens, and evaluated the safety. Results The ORR of mXELIRI and mFOLFIRI groups were 62.5% and 58.4%, the DCR were 87.5% and 88.9%, and the median PFS were 10.5 and 9.9 months, respectively (all P>0.05). The incidence of hand-foot syndrome (HFS) of mXELIRI group was significantly higher than that of mFOLFIRI group (37.5% vs. 13.9%, P=0.025). Conclusion Cetuximab combined with mXELIRI and mFOLFIRI in the first-line treatment of metastatic left-side colorectal cancer have equivalent efficacy and safety.